Roche (company)
FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment
Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement
FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer
Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends
Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study
Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends
Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration
Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio
Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011
From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics
Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry